ONCY Begins GOBLET Anal Cancer Cohort Enrollment Expansion Oncolytics Biotech® Begins Enrollment Expansion for GOBLET Anal Cancer Cohort
Successful stage 1 data support expansion, with nearly three times the objective response rate compared to checkpoint inhibitor monotherapy, including complete responses.
san diego and Calgary, Alberta, February 14, 2024 /PRNewswire/ — Oncolytic Biotechnology® Inc. (NASDAQ: Oncy) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced enrollment expansion of the anal cancer cohort of the GOBLET study evaluating the combination of perolep and atezolizumab (Tecentriq).®) Patients with unresectable squamous cell carcinoma of the anal canal (SCCA) after second-line treatment. This study expanded on positive data from Stage 1 of the study, which was presented at the 2nd Research Conference.n.d. International Interdisciplinary Anal Cancer Conference (IMACC) November 2023 (Link to PR, Link to poster).
“These exciting clinical data, exceeding Simon’s two-step success criteria, provide strong support for expanding the evaluation of peraleolep in patients with advanced anal cancer. Results reported at IMACC 2023 show that peraleolep in combination with atezolizumab demonstrated a 37.5% treatment efficacy.
These data demonstrate that post-second-line anal cancer patients treated with checkpoint inhibitor therapy experienced responses. This is in significant contrast to recent clinical trial results. 10-14% interest rate.1-3” said the doctor. matt coffey, President and CEO of Oncolytics. ”
“Given the early efficacy signals observed with peraleolep-based therapy, particularly in pancreatic cancer, we have a fairly optimistic outlook for our patients and the potential of peraleolep for stage 2 expansion. Currently, there is no established standard of care for patients with anal cancer who have failed the first line of therapy. Opportunities could expand and open the door to expedited regulatory pathways in this rare and grossly underserved patient population,” Dr. Coffey continued.
dirk arnold “One of the most difficult challenges in my practice is the limited number of treatment options available for patients with advanced anal cancer,” said Dr. M.D., director of the Asklepios Oncology Center [AIO] in Hamburg and principal investigator of the GOBLET trial. “It’s about being there,” he commented. This will allow continued evaluation of Pelaorep and atezolizumab combination therapy, as it may provide important confirmatory data that may lead to better treatment options for patients with this late-stage treatment drug. I’m working hard on growing this cohort. gradual disease. ”
“We look forward to building on the oncology community’s enthusiastic reception of the IMACC 2023 data by expanding enrollment in the anal cancer cohort and incorporating additional sites into the study.” did. thomas heineman, MD, Ph.D., Chief Medical Officer, Oncolytics. “Careful consideration of recently published clinical trial results suggests that even modest expansion of the number of patients to less than 20 patients would solidify the efficacy signal observed to date and provide guidance for future studies targeting this population. We find that this is sufficient to lay the foundation for a potential registration study. We hope to continue our excellent collaboration with AIO clinical sites and researchers and report additional results in 2025. Masu.”
https://drhimanshuyadav.com/oncolytics-biotech-begins-enrollment-expansion-for-goblet-anal-cancer-cohort/